Return to homepagePandemic Pact

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-RANGING STUDY TO COMPARE THE SAFETY AND EFFICACY OF 3 DOSE LEVELS OF AV-1 IN HEALTHY ADULTS CHALLENGED WITH A CONTROLLED HUMAN INFECTION S

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N93019D00031-P00001-759302300004-1

Grant search

Key facts

  • Disease

    Dengue

  • Start & end year

    2023
    2025

  • Known Financial Commitments (USD)

    $321,765

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    ASSOCIATE PROFESSOR Anna Durbin

  • Research Location

    United States of America

  • Lead Research Institution

    JOHNS HOPKINS UNIVERSITY

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Phase 2 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

To support a phase two clinical trial to evaluate a dengue vaccine candidate.